Byston J, Cech K, Pekarek J, Jilkova J
Dept. of Allergology and Clinical Immunology, Faculty Hospital, Olomouc, Czech Republic.
Biotherapy. 1996;9(1-3):73-5. doi: 10.1007/BF02628660.
Using a blood cell separator, lymphocytes were collected from otherwise healthy convalescents suffering from herpetic infections. A specific anti-herpes dialysate (AH-DLE) was prepared from the lymphocytes, using standard procedures. Patients with recurrent herpetic infections were treated with a single dose of the dialysate, at the initial signs of herpetic infection (group A), with two doses (group B) or with three doses (group C). A total number of 37 patients (29 women, 8 men, age range 15-73 years) were treated. No improvement was observed in 7 patients (18.9%), whilst 7 patients did not manifest any exacerbation of their herpetic infection in the course of the one-year follow-up. The remaining 62.2% of the patients showed a marked improvement: decrease of the frequency and/or duration or relapses. Before AH-DLE administration, the mean number of herpes relapses in this group of patients was 12 p.a.. After therapy, the number of relapses decreased to 3.5 p.a.. No statistically significant difference was observed between groups A and B. The least favourable results were registered in group C. However, this group included 6 female patients extremely resistant to the previously therapeutic attempts, including inosiplex, non-specific DLE or acyclovir. Thus, even in this group, the therapy was successful in 50% of the patients.
使用血细胞分离器，从患有疱疹感染的其他方面健康的康复者中收集淋巴细胞。使用标准程序从淋巴细胞中制备特异性抗疱疹透析液（AH-DLE）。复发性疱疹感染患者在疱疹感染初始迹象时接受单剂量透析液治疗（A组）、两剂量治疗（B组）或三剂量治疗（C组）。共治疗了37名患者（29名女性，8名男性，年龄范围15 - 73岁）。7名患者（18.9%）未见改善，而7名患者在一年随访期间疱疹感染未出现任何加重。其余62.2%的患者有明显改善：发作频率和/或持续时间降低以及复发减少。在给予AH-DLE之前，该组患者疱疹复发的平均次数为每年12次。治疗后，复发次数降至每年3.5次。A组和B组之间未观察到统计学上的显著差异。C组的结果最不理想。然而，该组包括6名对先前治疗尝试（包括肌苷磷钠、非特异性DLE或阿昔洛韦）极具抗性的女性患者。因此，即使在该组中，50%的患者治疗成功。
